Clinical trial
A Multi-Center Registry Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
NCT04312659 is registered in ClinicalTrials.gov with Johnson & Johnson (China) Investment Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center Registry Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
- Lead sponsor
- Johnson & Johnson (China) Investment Ltd.
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 15, 2020
- Completion date
- September 12, 2023
- Enrollment
- 38 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.